Rite Aid Addresses Cyberattack: 2.2 Million Customers’ Data Breached
Drug Topics
JULY 17, 2024
The retail pharmacy chain issued an alert to its customers that purchasing data from 2017 to 2018 may have been breached by a third party.
2017 Related Topics 
FDA: Fasenra Approved As Add-On Maintenance Therapy for Severe Pediatric Asthma
Drug Topics
APRIL 12, 2024
Fasenra was initially approved in 2017 as an add on maintenance therapy in patients aged 12 years and older.
FDA 
387
387 FDA 387
387 Join 5,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
STAT+: Life sciences deals on track to hit lowest point since 2017
STAT
OCTOBER 11, 2023
If dealmaking remains consistent for the rest of the year, it would put this year on par with the number of deals made in 2017. For comparison, there were roughly 2,122 financing deals made last year. Continue to STAT+ to read the full story…
132 
Preserving Patient Access to Compounded Medications Act of 2017
Pharmacy Times
SEPTEMBER 14, 2023
The act would have permitted health care facilities to stock up on compounded medications without forcing the supplying 503A pharmacies to register as outsourcing facilities.
Compounding 139
139 Compounding 139
139 
Adderall Shortage Led to More Alternative Stimulant Prescriptions for US Children
Drug Topics
JANUARY 27, 2025
Researchers analyzed overall prescription stimulant dispensing trends among US children from 2017 to 2023.
247 
STAT+: FTC slams PBMs for boosting specialty drug prices at the expense of the U.S. health care system
STAT
JANUARY 14, 2025
billion in revenue by dispensing medicines to treat cancer, HIV, heart disease and other serious illnesses at prices that exceeded their estimated acquisition costs between 2017 and 2022. Specifically, the companies were able to generate more than $7.3 Continue to STAT+ to read the full story…
Insurance 140
140 Insurance 140
140 
STAT+: Two of FDA’s top cancer regulators to depart, heightening worries about drug reviews
STAT
MARCH 27, 2025
The FDA’s Oncology Center of Evidence was created in 2017 by Congress as a way to speed the development of cancer treatments. Theoret, who joined as a medical reviewer in 2009, have told colleagues of plans to leave the FDA, multiple sources familiar with the matter told STAT.
FDA 105
105 FDA 105
105 
Updated USPSTF Guidelines Show Benefits of Screening for Obstructive Sleep Apnea Do Not Outweigh Harms
Pharmacy Times
DECEMBER 9, 2022
The decision is updated from a 2017 recommendation to screen people for obstructive sleep apnea, which can lead to daytime sleepiness and other adverse outcomes.
139 
PTC wins FDA approval for first brain-delivered gene therapy Kebilidi
Fierce Pharma
NOVEMBER 14, 2024
The FDA issued its first stamp of approval for a cell or gene therapy back in 2017 to Novartis' Kymriah. | The gene therapy has already been approved to treat AADC deficiency in Europe and the U.K., among other countries, where it's branded as Upstaza.
FDA 131
131 FDA 131
131 
Risks Facing Pharmacists, and Their Associated Costs, Are Increasing
Pharmacy Times
DECEMBER 21, 2023
The cost of defending license matters and malpractice claim costs have increased over a 5-year period (2017-2022).
132 
FDA Approves Cerliponase Alfa for Expanded Indication of CLN2 Disease
Pharmacy Times
JULY 24, 2024
In April 2017, the drug was approved to treat the slow loss of the ability to walk for symptomatic patients aged 3 and older who had Batten disease.
FDA 122
122 FDA 122
122 
Vision loss and high cholesterol identified as risk factors for dementia
STAT
JULY 31, 2024
These new additions join 12 other risk factors outlined by the commission, affiliated with University College London, in previous reports on dementia prevention, intervention, and care in 2017 and 2020.
145 
Public Health Matters - Loving the Pharmacy Profession, Helping Patients
Pharmacy Times
DECEMBER 22, 2022
Alex Barker founded The Happy PharmD to provide career coaching and career development classes, and since 2017, the company has helped over 1,500 pharmacists.
132 
STAT+: Belgian anti-trust authorities probe Roche for allegedly delaying biosimilars of two cancer meds
STAT
MARCH 17, 2025
In a brief statement , the Belgian Competition Authority alleged that Roche offered financial incentives to hospitals between 2017 and 2020 to deter them from considering competitive bids from other pharmaceutical companies that could supply similar medicines.
FDA Approves Benralizumab to Treat Pediatric Patients Aged 6 to 11 Years With Severe Asthma
Pharmacy Times
APRIL 11, 2024
Benralizumab was previously approved by the FDA in 2017 as an add-on maintenance therapy for patients 12 years and older.
FDA 111
111 FDA 111
111 
Federal officials and physician groups express outrage over revelations of recent coercive sterilizations
STAT
JUNE 6, 2024
Federal officials, medical organizations, and reproductive health advocacy groups have expressed outrage in response to STAT’s recent investigation revealing that women with sickle cell disease have felt pressured into sterilizations as recently as 2017 and 2022.
142 
Study points to weaknesses in FDA accelerated approval path
pharmaphorum
APRIL 8, 2024
Less than half of the cancer therapies given accelerated approval by the FDA in 2013 to 2017 showed a clinical benefit in a confirmatory trial within the next five years
FDA 110
110 FDA 110
110 
Avive pockets $57M for portable defibrillator to speed up cardiac arrest response
Fierce Healthcare
APRIL 19, 2024
The company, which launched in 2017, has contracts with four cities for its network of AEDs to improve survival rates of sudden cardiac arrest. Portable defibrillator company Avive Solutions raised $56.5 million in growth equity financing to build out its staff and commercial developments. |
115 
Heat waves associated with increased risk of preterm birth in the U.S.
STAT
MAY 28, 2024
A new investigation, published on Friday in JAMA Network Open , confirmed the link to early deliveries at a massive scale, in a large cohort study capturing over half of the births that occurred in the United States between 1993 and 2017. Its results shed light on the way existing health inequities may be exacerbated by a worsening climate.
133 
STAT+: As AI proliferates, biopharma companies seek to harness it in clinical trials
STAT
APRIL 3, 2024
That was until 2017, when he founded a startup called Nucleai. For around 20 years, Avi Veidman spent his days in the Israeli intelligence community, analyzing satellite images. Now, he’s scouring biopsy samples for cancer cells. Nucleai’s technology is not searching out signs of danger.
130 
With FDA nod for Onivyde combo, Ipsen ends 10-year drought in newly diagnosed pancreatic cancer
Fierce Pharma
FEBRUARY 13, 2024
It’s the approval Ipsen has been waiting for since buying up Onivyde in 2017. It’s the approval Ipsen has been waiting for since buying up Onivyde in 2017. The FDA has approved Onivyde as part of a combination dubbed Nalirifox to treat patients with newly diagnosed metastatic pancreatic cancer.
FDA 98
98 FDA 98
98 
STAT+: NYU professors who defended vaping didn’t disclose ties to Juul, documents show
STAT
MAY 6, 2024
Abrams, a frequent commentator about vaping in the news media, including CBS This Morning, CNN, and The New Yorker, coordinated extensively with Juul on public messaging in 2017 and 2018, according to company emails.
Documentation 145
145 Documentation 145
145 
Support for continued progress is critical for pediatric drug development
PhRMA
MAY 8, 2023
After ibrutinib was initially approved in 2017 for adult patients with cGVHD who have tried and failed on at least one previous medicine, the U.S. For example, ibrutinib was awarded BPCA pediatric exclusivity based on the sponsor’s research into use of the drug in pediatric chronic graft-versus-host disease (cGVHD) patients. After
FDA 264
264 FDA 264
264 
STAT+: How sickle cell became the first disease treated by CRISPR
STAT
DECEMBER 4, 2023
“We looked at anything and everything,” said Novak, who stepped down as CEO in 2017 but remained on the board until this year. His company, along with two others, were founded to commercialize the new revolutionary gene-editing tool CRISPR-Cas9 , which promised to cure numerous genetic diseases.
Documentation 143
143 Documentation 143
143 
Opinion: The U.S. should follow California’s lead on banning toxic chemicals in IV bags and tubes
STAT
SEPTEMBER 18, 2024
In 2017, at the age of 42, Susan Whitehead was diagnosed with an early form of breast cancer after discovering a lump in her breast. She embarked on a challenging path of treatment, including a recurrence with stage 2 cancer four years later. Susan underwent two lumpectomies, a mastectomy, radiation, and chemotherapy.
Chemotherapy 118
118 Chemotherapy 118
118 
STAT+: NIH postdocs will get a raise next year — but not as much as they hoped
STAT
APRIL 23, 2024
But the agency noted in a press release that it’s the largest year-over-year update for NIH-funded postdocs since 2017. The 8% pay bump is far short of the increase to $70,000 that was recommended by an NIH working group late last year.
131 
How doctors are pressuring sickle cell patients into unwanted sterilizations
STAT
MAY 21, 2024
She was seven months pregnant when the doctor brought it up in April 2017. She sat on the couch in the half-light, blinds shut against the heat. The whole thing made her feel less than, like some essential part of her had been removed. She shouldn’t eat before the operation.
145 
Bill Nye, Science Guy, speaks out on ataxia
STAT
OCTOBER 10, 2024
Nye has previously spoken about the genetic disease, which makes it difficult for people with the condition to control their muscles and often leads to problems with walking and speech, in a documentary released in 2017. He said then that he didn’t have children because of concerns he would pass on the disease to them.
129 
STAT+: Addiction treatment center founder indicted in sprawling fraud scheme
STAT
MAY 24, 2023
Over the last few years, Daniel Cleggett Jr. appeared to be living a charmed life.
145 
'Most' cancer meds approved under FDA's accelerated pathway couldn't prove survival benefit after 5 years: study
Fierce Pharma
APRIL 8, 2024
Many cancer meds approved under the FDA's accelerated approval pathway from 2013 to 2017 didn't improve overall survival after more than five years of follow-up research, the study found. One hallmark of the FDA's accelerated approval pathway is the requirement that medicines prove their benefits in confirmatory trials.
FDA 103
103 FDA 103
103 
STAT+: They carry a gene for ALS but aren’t sick. What does medical research owe them?
STAT
SEPTEMBER 21, 2023
Her mom, Kathy Cronin, lived her life in fear of the disease, an anxiety both her children and her doctors dismissed, until, in the summer of 2017, she developed symptoms that were impossible to ignore. It took her great-grandfather before she was born and her grandmother when she was 6 years old.
144 
Roche doubles down with another subcutaneous FDA nod, this one for MS star Ocrevus
Fierce Pharma
SEPTEMBER 13, 2024
When Roche's Genentech gained approval for Ocrevus in 2017, the first-in- | The day after Roche gained an FDA approval for its subcutaneous version of cancer drug Tecentriq, the company also scored with a U.S. nod for its under-the-skin formulation of mega-blockbuster multiple sclerosis drug Ocrevus.
FDA 105
105 FDA 105
105 
Pharmaceutical training boost: how the growth and skills levy could shape industry development
European Pharmaceutical Review
FEBRUARY 17, 2025
Growth and Skills Levy – enabling greater training flexibility Since its introduction in 2017, the Apprenticeship Levy has generated over 21 billion from UK employers, increasing apprenticeship funding from 1.5 billion in 2017/18 to 2.5 billion in 2023/24.
STAT+: About half of cancer drugs given accelerated approval don’t improve survival or quality of life
STAT
APRIL 7, 2024
years after accelerated approval for cancer drugs to be pulled from the market if follow-up trials didn’t show a benefit; by 2017, that timing dropped to 3.6 The study also found evidence that drugs granted accelerated approval, meant to be a temporary designation, are spending less time in limbo. In 2013, it took an average of 9.9
FDA 143
143 FDA 143
143 
STAT+: Telehealth providers can drive antibiotic overuse — or choose to combat it
STAT
APRIL 11, 2024
In 2017, after receiving reports about the telehealth site, an investigator for the California medical board logged on to Lemonaid using an alias. Ho Anh had just started working at Lemonaid Health when he was caught up in a sting.
130 
Radiopharmaceuticals reach record high with $408m in venture financing for 2023
Pharmaceutical Technology
NOVEMBER 28, 2023
Venture financing for innovative radiopharmaceutical drugs witnessed an approximately 550% increase from $63m in 2017 to $408m in 2023 YTD (year-to-date) total deal value in the US.
98 
STAT+: Pear Therapeutics sold for parts at $6 million auction
STAT
MAY 19, 2023
The company received the first FDA clearance for a standalone digital therapeutic in 2017 for reSET, a product that used cognitive behavioral therapy to treat substance use disorder. It was followed by clearances for reSET-O, an app for opioid use disorder, and Somryst, for insomnia.
FDA 140
140 FDA 140
140 
Medical device companies pay millions to NHS while pushing products, says study
The Guardian - Pharmaceutical Industry
APRIL 20, 2024
An analysis of disclosures by medical device companies found that between 2017 and 2019 they reported €425m (£367m at today’s rates) in payments to healthcare organisations in Europe, according to the study in the journal Health Policy and Technology. Continue reading.
Hospitals 105
105 Hospitals 105
105 
STAT+: AbbVie dramatically outspent its pharma company rivals in 2023 to promote its drugs to doctors
STAT
JULY 5, 2024
The massive sum spent by AbbVie, the maker of the mega blockbuster anti-inflammatory drug Humira, is the most a pharmaceutical company has spent on marketing to doctors since such data became available in 2017.
STAT+: A Q&A with the CEO of CRISPR Therapeutics on a historic approval and the road ahead
STAT
DECEMBER 8, 2023
In 2017, he was elevated to CEO. Samarth “Sam” Kulkarni has been there from almost the beginning. The former McKinsey partner joined CRISPR Therapeutics in 2015 as its chief business officer. STAT spoke to Kulkarni about how the company reached this point, and where the field of CRISPR-based medicine is going.
127 
STAT+: Startup Laronde merges with another biotech in wake of data integrity issue
STAT
OCTOBER 19, 2023
Laronde was founded by biotech creation firm Flagship Pioneering in 2017 to develop a new type of genetic medicine called endless RNA. RNA medicines startup Laronde is merging with another startup in the wake of a scientific misconduct issue that affected its leading drug candidates.
132 
STAT+: Jury orders Stanford to pay millions to employee in racial harassment case
STAT
JUNE 21, 2024
The employee, patient testing technician Qiqiuia Young, alleged in a 100-page lawsuit filed in 2017 that problems began when her co-workers at Stanford Cancer Center dressed as members of the Ku Klux Klan around Halloween.
Hospitals 130
130 Hospitals 130
130 
Idorsia's Tryvio crosses FDA finish line, offering new mechanism to treat hypertension
Fierce Pharma
MARCH 20, 2024
After Johnson & Johnson last year changed its mind on its 2017 purchase of ap | Idorsia's Tryvio is the first oral anti-hypertensive therapy that uses a new therapeutic mechanism in nearly 40 years, suggesting the dawn of "a new era of endothelin research," the company said.
FDA 103
103 FDA 103
103 
Opinion: The FDA needs to embrace phage therapy to help fight antimicrobial resistance
STAT
JUNE 23, 2024
My daughter, Mallory, died in 2017 at the age of 25 from a multiply resistant bacterial lung infection that followed a double-lung transplant necessitated by cystic fibrosis.
FDA 134
134 FDA 134
134 
Let's personalize your content